CHEK2 and ovarian carcinoma: More specifically, we have tested prexasertib, an intravenously administered Chk1/Chk2 inhibitor which recently demonstrated promising clinical activity in heavily pretreated BRCA wild-type patients with recurrent ovarian cancer [35] and is currently part of multiple combinatory clinical trials.